PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma

Nuclear Medicine Communications

Volumn 32, Issue 7, 2011, Pages 563-569

  Sadri, Kayvan ^a   Ren, Qing ^a   Zhang, Kaijun ^a   Paudyal, Bishnuhari ^a   Devadhas, Devakumar ^a   Rodeck, Ulrich ^a   Thakur, Mathew ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

64Cu cetuximab; epidermal growth factor receptor expression; MDA MB 468; positron emission tomographic imaging of breast cancer; receptor binding

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CETUXIMAB CU 64; CETUXIMAB; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 79958771082     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283419523     Document Type: Article

References (20)

1. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Current Pharmaceutical Design 2008; 14:2983-2998.
2. Laskin JJ, Sandler AB. Epidermal growth factor receptors: a promising target in solid tumors. Cancer Treat Rev 2004; 30:1-17. (Pubitemid 38240085)
3. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Ann Rev Biochem 2006; 75:93-109. (Pubitemid 44118027)
4. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P. Tyrosine kinase receptors as attractive targets for cancer therapy. Crit Rev Oncol Hematol 2004; 50:23-28.
5. Li S, Schmitz K, Jeffrey P,Wiltzius J, Kussie P, Ferguson K. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-311. (Pubitemid 40544648)
6. Wong S. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005; 27:684-694. (Pubitemid 41583517)
7. Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28:8-14.
8. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using (64)Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34:850-858.
9. 64Cu BAT-2IT-1A3. Cancer Biother Radiopharm 2001; 16:483-494.
10. Thakur ML, Richard MD, White FW. Monoclonal antibodies as agents for selective radiolabeling of human neutrophils. J Nucl Med 1988; 29:1817-1825. (Pubitemid 18264915)
11. 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008; 49:1472-1479.
12. 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharma 2008; 23:158-171.
13. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol 2002; 54:1180-1193. (Pubitemid 35292632)
14. Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 2006; 5:104-113.
15. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-286. (Pubitemid 40590264)
16. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23:3536-3544.
17. 64Cu] chelator-peptide nucleic acid-IGF1 analog radiohybridization probes. J Nucl Med 2007; 48:1699-1707.
18. Zhang K, Aruva MR, Shanthly N, Cardi CA, Rattan S, Patel C, et al. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med 2008; 49:112-121.
19. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-1318.
20. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. Natl Cancer Inst 1989; 81:1616-1625. (Pubitemid 19264044)